Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
March 20, 2023 08:30 ET
|
Nurix Therapeutics, Inc.
-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- FOSTER CITY, Calif. and...
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting
March 14, 2023 16:45 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
February 09, 2023 16:15 ET
|
Nurix Therapeutics, Inc.
Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
February 08, 2023 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities
January 09, 2023 08:35 ET
|
Nurix Therapeutics, Inc.
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix’s...
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
December 15, 2022 16:01 ET
|
Nurix Therapeutics, Inc.
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in...
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022 17:30 ET
|
Nurix Therapeutics, Inc.
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK...
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
December 07, 2022 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...